Validating Software Products For Life Sciences Compliance
Webinar Added: 10/07/24
Watch now as GlobalScot Ray McKinney who has spent three decades working in regulatory compliance for software in life sciences, seeks to guide companies navigating the complexities of dealing with regulators.
Meeting the expectations of the US FDA, and other regulatory bodies around the world, presents a substantial hurdle when introducing any new software product serving the life sciences industries. Whether critical-to-life code like that in a pacemaker, or something as seemingly simple as a training database for pharmaceutical firms, developers are expected to be able to prove they have followed a documented software development lifecycle (SDLC) with risk-appropriate design and test documentation.
A successful software product introduction requires achieving a careful balance between the competing forces of time-to-market, validation cost, and consequences of compliance failure. Determining how-much-is-enough is often the subject of passionate debate.
This talk by GlobalScot Ray McKinney seeks to outline approaches to overcoming the compliance hurdles of the pharmaceutical and medical device industries. The goal is to allow developers to plan with confidence and help demystify a subject often shrouded in myth.
Scottish Enterprise Privacy Notice
Other events and webinars
Past, Present And Futureproofing: Evelyn Simpson
What needs to change to help women-led businesses get more investment? Self proclaimed 'startup finance geek', GlobalScot Evelyn Simpson is highly respected for her work supporting women-led businesses and advocating increased investment in them. Her past experience in finance took her to Asia. Since becoming a GlobalScot she now chairs charity Venture Scotland.
Market Opportunities In The Kingdom Of Saudi Arabia (KSA)
Watch now: as Scottish Development International facilitates a fascinating webinar on the lucrative opportunities in a food and drink market that is projected to grow from $14.16 billion in 2022 to $30.47 billion by 2029.